Harpoon Therapeutics harpoontx.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Harpoon Therapeutics is an immuno-oncology company focused on the discovery and development of T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created an antibody-based drug discovery platform called TriTAC (tri-specific T-cell activating construct) to unleash the targeted cell-killing properties of a patient's own immune system through T-cell activation. This approach has been created to penetrate tissues and extend serum exposure and has the poten...Show all

Harpoon Therapeutics is an immuno-oncology company focused on the discovery and development of T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created an antibody-based drug discovery platform called Tri...Show all

Company (Alive / Active)

Phone: 650-443-7400

Fax:

4000 Shoreline Ct
#250
South San Francisco, 94080
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Harpoon Therapeutics $45M May 25, 2017
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Harpoon Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors

Competitors

Company Status Description Investors

BeneVir Biopharm

Rockville, Maryland, United States
AcquiredBeneVir is a privately held biopharmaceutical company founded in 2011 with offices and laboratories located in Rockville, MD. BeneVir is developing a novel platform of cancer immuno-therapies based on oncolytic viruses to help patients with hard-to-treat cancers. In 2012, BeneVir received two Small Business Innovation Research (SBIR) grants from the National Cancer Institute, which supported proof-of-concept studies. BeneVir's immunotherapies for cancer are designed to induce the immune system t...Show allLogin to see details

Neon Therapeutics

Cambridge, Massachusetts, United States
IPO / Went publicNeon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. Neon's lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and...Show allLogin to see details
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Single domain serum albumin binding protein Sep 14, 2017 Mar 20, 2018 Patent
Trispecific binding proteins and methods of use May 20, 2016 Jul 18, 2017 Patent
Single chain variable fragment cd3 binding proteins Sep 14, 2017 Application
Trispecific binding proteins and methods of use Jun 22, 2017 Application
Single chain variable fragment cd3 binding proteins May 19, 2017 Application
See all 6 patents